The p38 MAPK inhibitor SB203580 blocks adenosine A(1) receptor-induced attenuation of in vivo myocardial stunning.

Abstract:

:There is considerable evidence implicating a key role for p38 mitogen-activated protein kinase (MAPK) in ischemic and pharmacological preconditioning against myocardial infarction. However, there have been few, if any, studies examining the role of p38 MAPK in the protection of stunned myocardium. The purpose of this study was to determine whether p38 MAPK plays a role in the adenosine A(1) receptor anti-stunning effect in in vivo porcine myocardium. Regional myocardial stunning in anesthetized, open-chest pigs was induced by 15 min of left anterior descending coronary artery (LAD) occlusion and 3 h of reperfusion (RP). Animals were treated with either vehicle (n = 5), AMP579 (70 microg/kg i.v.; 25 microg/kg bolus + 1.5 microg/kg/min for 30 min prior to ischemia, n = 5), the p38 MAPK inhibitor SB203580 (0.25 mg/kg i.v. bolus, n = 4) or a combination of SB203580 plus AMP579 (n = 5). Regional ventricular function was monitored by measurements of segment shortening and load insensitive parameters including preload recruitable stroke work (PRSW) and PRSW area (PRSWA). The ischemic area at risk was similar in all groups and there was no necrosis in any heart. Treatment with AMP579 significantly improved reperfusion regional PRSW and PRSWA compared to vehicle controls. The p38 inhibitor SB203580 alone did not alter the extent of myocardial stunning, but it abolished the beneficial effect of AMP579 pretreatment. These results provide the first evidence that p38 MAPK activation may play an important role in the mechanism by which adenosine agonists attenuate myocardial stunning.

journal_name

Cardiovasc Drugs Ther

authors

Yoshimura Y,Kristo G,Keith BJ,Jahania SA,Mentzer RM Jr,Lasley RD

doi

10.1007/s10557-004-6220-4

subject

Has Abstract

pub_date

2004-11-01 00:00:00

pages

433-40

issue

6

eissn

0920-3206

issn

1573-7241

journal_volume

18

pub_type

杂志文章
  • Comparison between ischaemic and anisomycin-induced preconditioning: role of p38 MAPK.

    abstract::To further evaluate the significance of p38 MAPK as trigger or mediator in ischaemic preconditioning, anisomycin and SB 203580 were used to manipulate its activation status. Special attention was given to the concentration of the drugs and protocols used. The isolated perfused rat heart, subjected to either 25 min glo...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1026116022552

    authors: Lochner A,Genade S,Hattingh S,Marais E,Huisamen B,Moolman JA

    更新日期:2003-05-01 00:00:00

  • Fish oil and the prevention and regression of atherosclerosis.

    abstract::Epidemiological studies in the seventies have put forward that dietary rather than genetic factors are responsible for the lower incidence of ischemic heart disease in Greenland Inuit and have generated a large body of both in vitro and in vivo experimental studies, exploring the putative favorable effects of fish (oi...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00877326

    authors: Sassen LM,Lamers JM,Verdouw PD

    更新日期:1994-04-01 00:00:00

  • The Melatonin Receptor Agonist Ramelteon Induces Cardioprotection that Requires MT2 Receptor Activation and Release of Reactive Oxygen Species.

    abstract:PURPOSE:The melatonin receptor (MT) agonist ramelteon has a higher affinity to MT1 than for MT2 receptors and induces cardioprotection by involvement of mitochondrial potassium channels. Activation of mitochondrial potassium channels leads to release of free radicals. We investigated whether (1) ramelteon-induced cardi...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-06972-4

    authors: Stroethoff M,Goetze L,Torregroza C,Bunte S,Raupach A,Heinen A,Mathes A,Hollmann MW,Huhn R

    更新日期:2020-06-01 00:00:00

  • Calcium antagonists and myocardial infarction.

    abstract::In vitro and in vivo studies have demonstrated many similarities between the three calcium antagonists verapamil, nifedipine, and diltiazem in relation to protection of the myocardium during hypoxia. Important clinical differences exist between the three drugs when they are used during or after an acute myocardial inf...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03029738

    authors: Hansen JF

    更新日期:1991-08-01 00:00:00

  • TAK1-AMPK Pathway in Macrophages Regulates Hypothyroid Atherosclerosis.

    abstract:PURPOSE:Hypothyroidism (HT) is associated with accelerated atherosclerosis (AS). The efficacy of traditional strategies of hypothyroid AS remains controversial. Here, we aimed to deepen the understanding of the HT-induced acceleration of AS, to decrease the residual risk of coronary artery disease (CAD) and to find a n...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-06996-w

    authors: Yang Y,Jia Y,Ning Y,Wen W,Qin Y,Zhang H,Du Y,Li L,Jiao X,Yang Y,Liu G,Huang M,Zhang M

    更新日期:2020-06-03 00:00:00

  • Comparative study of time-course of hemodynamic effect of isosorbide dinitrate spray and sublingual tablets in patients with pulmonary congestion.

    abstract::We compared the time-course of the hemodynamic effect of isosorbide dinitrate (ISDN), 5 mg, in the form of sublingual tablet and oral spray, in 15 patients with isolated chronic pulmonary congestion (pulmonary arterial end-diastolic pressure of 15 mmHg or more in the presence of normal or only slightly reduced cardiac...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00051192

    authors: Marchionni N,De Bari M,Ferrucci L,Moschi G,Schneeweiss A

    更新日期:1988-11-01 00:00:00

  • Alterations in the prognosis of chronic heart failure: an overview of the major mortality trials.

    abstract::Treatment of chronic heart failure (CHF) remains a major medical problem. Although in the last decades the benefits of several therapies in different patient populations with left ventricular dysfunction have been established, morbidity and mortality of CHF patients are high. Consequently, in the last decade improveme...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,meta分析

    doi:10.1023/a:1007786019054

    authors: Szabó BM,van Veldhuisen DJ,de Graeff PA,Lie KI

    更新日期:1997-07-01 00:00:00

  • Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent.

    abstract::Colesevelam hydrochloride (colesevelam) is a novel, potent, bile acid-binding agent that has been shown to lower LDL cholesterol a mean of 19% at a dose of 3.8 g/d. We studied the pharmacokinetics of colesevelam coadministered with six drugs: digoxin and warfarin, agents with narrow therapeutic indices; sustained-rele...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1007831418308

    authors: Donovan JM,Stypinski D,Stiles MR,Olson TA,Burke SK

    更新日期:2000-12-01 00:00:00

  • Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation.

    abstract:PURPOSE:The aim of this study was to evaluate the efficacy and safety of intravenous infusion of low-dose flecainide (50 mg) followed by oral pilsicainide (50 mg t.i.d.)in patients with paroxysmal atrial fibrillation (AF). METHODS:Thirty-one patients with symptomatic and hemodynamically stable AF lasting less than 48 ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,信件

    doi:10.1023/a:1024368111557

    authors: Nagai S,Takeishi Y,Kubota I

    更新日期:2003-01-01 00:00:00

  • Imaging of myocardial metabolism by positron emission tomography.

    abstract::Tracer techniques have provided new insight in cardiology by allowing noninvasive studies of myocardial perfusion, function, metabolism, and, more recently, ligand-receptor interaction. Positron emission tomography allows accurate quantification and the use of natural substrates labelled with 11C, 13N, or 15O. Myocard...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00051291

    authors: Rigo P,de Landsheere C,Melon P,Kulbertus H

    更新日期:1990-08-01 00:00:00

  • Inhibition of the cerebral renin-angiotensin system to limit cognitive decline in elderly hypertensive persons.

    abstract::Inhibition of then renin-angiotensin system (RAS) ranks among the best established and most used cardiovascular therapies. By providing protection against hypertension and heart failure, and also the microvascular complications of diabetes, RAS inhibitors have contributed to the longer life-expectancy now found in hig...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 社论

    doi:10.1007/s10557-011-6316-6

    authors: Opie LH

    更新日期:2011-08-01 00:00:00

  • Protective effects of hydrogen sulfide against chronic alcohol intake-induced left ventricular remodeling in rats.

    abstract:PURPOSE:To investigate the protective effects of hydrogen sulfide (H(2)S) against chronic alcohol intake-induced left ventricular remodeling and explore the potential mechanisms involved. METHODS:Rats were randomly divided into 4 groups: alcohol group, NaHS group, alcohol + NaHS group, and control group. The echocardi...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-013-6441-5

    authors: Zhou X,Lu X,Xu W,Chen J

    更新日期:2013-06-01 00:00:00

  • Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents for patients with coronary artery disease: an update meta-analysis.

    abstract:OBJECTIVE:Permanent polymer drug-eluting stents (DES) are associated with a higher risk of late and very late stent thrombosis (ST); biodegradable polymer drug-eluting stents (BP-DES) were designed to reduce these risks. However, their benefits are not completely clear. METHOD:We undertook a meta-analysis of randomize...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10557-014-6528-7

    authors: Wang Y,Dong P,Li L,Li X,Wang H,Yang X,Wang S,Li Z,Shang X

    更新日期:2014-08-01 00:00:00

  • Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse.

    abstract:PURPOSE:Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-012-6389-x

    authors: Toldo S,Schatz AM,Mezzaroma E,Chawla R,Stallard TW,Stallard WC,Jahangiri A,Van Tassell BW,Abbate A

    更新日期:2012-06-01 00:00:00

  • Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.

    abstract:AIMS:Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicenter observational study were to determine the safety and effectiveness of intravenous (IV) vernakalant...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07103-9

    authors: Lévy S,Hartikainen J,Ritz B,Juhlin T,Carbajosa-Dalmau J,Domanovits H

    更新日期:2020-11-18 00:00:00

  • Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.

    abstract::The antihypertensive effects of once-daily administration of celiprolol 400 mg were compared with those of once-daily enalapril 20 mg in 20 mild to moderate essential hypertensives in a single-blind study in which the subjects were randomized to 2 weeks' treatment with either drug, preceded by 2 weeks of placebo admin...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00051236

    authors: Ghiringhelli S,Cozzi E,Tsialtas D

    更新日期:1988-07-01 00:00:00

  • Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition.

    abstract::Cilazapril, an angiotensin-converting enzyme inhibitor, and mibefradil, a selective T-type voltage-operated calcium channel blocker, have been shown to prevent neointima formation after vascular injury. The goal of the present study was to evaluate the mechanism of action of both drugs. For this purpose, the influence...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00823586

    authors: Schmitt R,Clozel JP,Iberg N,Bühler FR

    更新日期:1996-05-01 00:00:00

  • Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.

    abstract::In both epidemiologic and genetic studies, increased levels of Lp(a) have been associated with increased risk for cardiovascular diseases as well as aortic stenosis. However, until recently, it has been difficult to lower levels of Lp(a). Diet and lifestyle have little effect on plasma levels of Lp(a) which are mainly...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-016-6654-5

    authors: Stein EA,Raal F

    更新日期:2016-02-01 00:00:00

  • Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique.

    abstract::True positive inotropy of enoximone is hard to prove clinically. It could increase the risk of myocardial ischemia when used in coronary artery disease (CAD). The analysis of the end-systolic pressure-volume relationship (ESPVR) as a load-independent parameter of the contractile left ventricular function (LVF) allows ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF02018269

    authors: Thormann J,Hueting J,Kremer P,Wissemann J,Mitrovic V,Dieterich HA,Schlepper M

    更新日期:1990-10-01 00:00:00

  • How do calcium antagonists differ in clinical practice?

    abstract::The majority of calcium antagonists used clinically belong to three distinct chemical classes: the phenylalkylamines, the dihydropyridines, and the benzothiazepines. In recent years their mode of action has been unravelled, their limitations recognized, and their efficacy and use in the management of patients with a b...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00877225

    authors: Ferrari R,Cucchini F,Bolognesi R,Bachetti T,Boraso A,Bernocchi P,Gaia G,Visioli O

    更新日期:1994-08-01 00:00:00

  • Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans.

    abstract::To compare the antiischemic effects of intracoronary administration of a beta blocker, atenolol, and of a calcium antagonist, nifedipine, on the clinical and electrocardiographic signs of myocardial ischemia induced by balloon occlusion of the coronary artery, we studied 32 consecutive patients undergoing routine PTCA...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00051147

    authors: Ghio S,De Servi S,Angoli L,Bramucci E,Eleuteri E,Raffaghello S,Specchia G

    更新日期:1992-06-01 00:00:00

  • Encainide.

    abstract::Encainide is a class IC antiarrhythmic agent having little or no effect on action-potential duration or maximum diastolic potential but decreasing the maximum rate of phase O depolarization as well as increasing atrial and ventricular effective refractory periods. In intact animals or humans, encainide increases the A...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF01857621

    authors: Antonaccio MJ,Gomoll AW,Byrne JE

    更新日期:1989-10-01 00:00:00

  • KT-362 related effects on intracellular calcium release and associated clinical potential: arrhythmias, myocardial ischemia, and hypertension.

    abstract::The following discourse addresses the pharmacologic profile of KT-362, its clinical potential as an anti-arrhythmic agent with associated hypotensive effects, as well as its additional related potential in myocardial ischemia and related sequellae, and the specific cellular actions that may be responsible for these po...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF02018262

    authors: Hester RK,Shibata S

    更新日期:1990-10-01 00:00:00

  • Neurocardiogenic syncope in selected pediatric patients--natural history during long-term follow-up and effect of prophylactic pharmacological therapy.

    abstract:OBJECTIVE:The natural history of pediatric patients with severely symptomatic neurocardiogenic syncope is poorly defined respect to the likelihood of remission or symptomatic recurrence along time. We undertook this study to investigate the likelihood of clinical relapse, and to assess the effect of prophylactic pharma...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1011179014084

    authors: Biffi M,Boriani G,Bronzetti G,Frabetti L,Picchio FM,Branzi A

    更新日期:2001-03-01 00:00:00

  • Alternatives to mega-trials in cardiovascular disease.

    abstract::This article considers the dominant role of trials involving thousands of patients--the mega-trials--in cardiovascular disease. Problems with large trials mean that alternative strategies must be developed to aid the introduction of new drugs. The limitations of meta-analysis, and of trials with combined and surrogate...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00053034

    authors: Hampton JR

    更新日期:1997-01-01 00:00:00

  • Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.

    abstract:PURPOSE:To evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against ischemia-reperfusion injury. METHODS:Human cardiomyocytes (HCMs), cardiomyocytes from cardiac-specific PPARγ knockout (MCM-PPARγ (CKO) ) or wild type (MCM-WT) mice were incubated with different ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-016-6650-9

    authors: Qian J,Chen H,Birnbaum Y,Nanhwan MK,Bajaj M,Ye Y

    更新日期:2016-04-01 00:00:00

  • Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).

    abstract::To evaluate cordiodepressive risks of antiarrhythmic treatment with diprafenone, we monitored, in addition to conventional hemodynamic parameters, end-systolic pressure-volume relations to assess potential negative inotropic effects. Thirteen patients underwent hemodynamic analysis with and without the influence of di...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01883858

    authors: Thormann J,Kramer W,Kremer P,Schlepper M

    更新日期:1989-04-01 00:00:00

  • Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.

    abstract::We used Folts' model of critical coronary artery stenosis with endothelial damage, which measures platelet-rich thrombus accumulation from cyclic flow reductions (CFRs). This paper reports results applied to trimetazidine, a member of the piperazine group. Trimetazidine at a dose of 1 mg/kg completely abolished CFRs c...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00878324

    authors: Belcher PR,Drake-Holland AJ,Hynd JW,Noble MI

    更新日期:1993-02-01 00:00:00

  • Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine.

    abstract::The purpose of the present study was to test whether the administration of a vascular-selective organic calcium antagonist (nisoldipine) at the onset of early mechanical reperfusion (by coronary angioplasty) in acute myocardial infarction could prevent or attenuate postischemic stunning and enhance the recovery of lef...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1007713118941

    authors: Sheiban I,Tonni S,Chizzoni A,Marini A,Trevi G

    更新日期:1997-03-01 00:00:00

  • The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig.

    abstract::The effects of oral zofenopril pretreatment were investigated in a chronic closed-chest pig model of ischemia and reperfusion. Pigs (25-35 kg) were pretreated orally with zofenopril (15 mg/day) on the 2 days prior to ischemia, which was evoked by the inflation of a catheter balloon in the left anterior descending coro...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01856557

    authors: Tio RA,de Langen CD,de Graeff PA,van Gilst WH,Bel KJ,Wolters KG,Mook PH,van Wijngaarden J,Wesseling H

    更新日期:1990-06-01 00:00:00